Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant (TAMARO)

June 11, 2009 updated by: Institut Claudius Regaud

Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors

This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane (Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for exemestane and 20 mg / day for 4 months for tamoxifen.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Toulouse, France
        • Institut Claudius Regaud
      • Toulouse, France
        • CHU de Toulouse Rangueil

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Breast cancer histologically proven by a 14 G or 16 G micro-biopsy to have confirmation of the diagnosis, evaluation histology prognosis grade, hormone receptors and to obtain a sample for the study of biological factors.

  • Menopausal patients as defined as follows:

    • Natural menopause >= 1 year, or
    • Surgical ovariectomy.
  • T unilateral tumor> 3 cm, N 1-2, M0 or M +, non-inflammatory.
  • Hormone receptor positive. RE positive or PR positive with histochemical technique (+ 10% of cells express the receptor)
  • No previous treatment of the disease by chemotherapy, hormone therapy, surgery or radiotherapy. Discontinuation of replacement therapy of menopause for at least 1 month
  • Age>= 60 years
  • Evaluable disease
  • Performance Status <= 2

  • Biological function using the following criteria:

    • neutrophils >= 2.10E9 / l,
    • Platelets> = 100.10E9 / l,
    • Hemoglobin> = 10 g / dl,
    • Creatinine <= 1.5 x upper normal,
    • Total bilirubin <= 1.25 x the upper normal
    • Transaminases (AST and ALT) <= 1.5 x upper normal,
    • Alkaline phosphatase <= 2.5 x upper normal.
  • Cardiac Function: electrocardiogram (ECG) normal.
  • Signed written consent before any procedure related to the study.

Exclusion Criteria:

  • Men
  • Non Menopausal Patients
  • Patients with hormone receptor negative: PR- and RE -
  • Contra-indication to anti-estrogens (risk thrombi arteria)
  • Tumor <3 cm operable
  • Tumor inflammatory T4d (PEV 2 or 3).
  • Extensive hepatic lesions (> 1 / 3 of liver volume)
  • Uncontrolled cardiac disease such as angina, congestive heart failure, or arrhythmia requiring medical treatment or history of myocardial infarction within 3 months before.
  • History of cancer except skin cancer and basal cell cancer in situ of the cervix (a contralateral breast cancer had been no systemic treatment will be admitted).
  • Chronic diseases (somatic or psychiatric) in poor prognosis.
  • Patients who for reasons of family, social, geographical or psychological can not be followed properly.
  • Patients under law protection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Evaluate the objective response rate (complete response and partial response)
Time Frame: June 2006
June 2006

Secondary Outcome Measures

Outcome Measure
Time Frame
Pharmacokinetic interaction between Exemestane and Tamoxifen
Time Frame: june 2006
june 2006

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut Claudius Regaud

Collaborators

PHARMACIA SAS

Investigators

  • Principal Investigator: Henri ROCHE, Institut Claudius Regaud

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2002

Primary Completion (Actual)

June 1, 2006

Study Completion (Actual)

June 1, 2006

Study Registration Dates

First Submitted

June 11, 2009

First Submitted That Met QC Criteria

June 11, 2009

First Posted (Estimate)

June 12, 2009

Study Record Updates

Last Update Posted (Estimate)

June 12, 2009

Last Update Submitted That Met QC Criteria

June 11, 2009

Last Verified

June 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 01 SEIN 03

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Neoplasms

Clinical Trials on Exemestane

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe